Amgen Inc.’s Stock Price Soars to $410.24, Marking a Robust 4.34% Increase

Amgen Inc. (AMGN)

410.24 USD +17.08 (+4.34%) Volume: 3.55M

Amgen Inc.’s stock price has surged to a robust 410.24 USD, marking a significant trading session increase of +4.34%. With a trading volume of 3.55M and an impressive YTD percentage change of +25.34%, investors are closely monitoring AMGN’s bullish performance in the market.

Latest developments on Amgen Inc.

Amgen Inc. has seen a surge in stock price today following the announcement of positive topline Phase 3 results for their autoimmune drug, Dazodalibep, in treating moderate-to-severe systemic Sjögren’s disease. This success comes after Amgen posted a trial win for the same drug, showing promising outcomes for patients with this autoimmune condition. The company’s stock outperformed competitors on a strong trading day, with analysts highlighting Amgen’s edge in the market. With the drug meeting key test goals and achieving a Phase 3 win, investors are optimistic about Amgen’s future prospects, leading to a 3.90% increase in their stock price on September 22. Amgen’s innovative approach to drug development and their robust pipeline continue to attract attention and drive growth in the market.

Amgen Inc. on Smartkarma

Analysts on Smartkarma are bullish on Amgen Inc, with reports from Baptista Research and αSK Primers highlighting the company’s strong performance and strategic growth initiatives. Baptista Research‘s report on Amgen’s second-quarter performance emphasized a 26% year-over-year growth driven by key growth drivers across various segments. Meanwhile, αSK Primers discussed Amgen’s strategic navigation through a transition period, focusing on the potential of their late-stage pipeline and recent acquisitions to drive future growth.

Furthermore, Baptista Research‘s analysis of Amgen’s first-quarter performance in 2026 showcased a 4% growth in product sales and the significant contribution of key growth drivers to the company’s overall sales. Despite challenges from patent expirations and competitive pressures on legacy products, Amgen’s diversified portfolio spanning various therapeutic areas positions them well for sustained growth. Investors are closely monitoring developments such as the potential breakthrough in obesity treatment with the candidate MariTide (AMG 133), as highlighted in αSK Primers’ report on Amgen’s strategic outlook.

A look at Amgen Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Amgen Inc. has been given a high score of 5 for its Dividend outlook, indicating a strong potential for consistent dividend payments to investors. This suggests that the company is financially stable and has the ability to generate steady returns for shareholders through dividends.

While Amgen Inc. received a lower score for its Value outlook at 2, the company still shows promise with scores of 3 for Growth and Resilience, as well as a score of 4 for Momentum. This suggests that Amgen Inc. has potential for growth and is resilient in the face of challenges, with positive momentum in the market. Overall, Amgen Inc. remains a strong player in the biotechnology industry, focusing on developing innovative medicines for serious diseases.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma